| Item Type | Name |
|
Concept
|
Academic Medical Centers
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Ethics, Medical
|
|
Concept
|
Economics, Medical
|
|
Concept
|
Medical Records
|
|
Concept
|
Societies, Medical
|
|
Concept
|
Medical Oncology
|
|
Concept
|
Renal Insufficiency, Chronic
|
|
Concept
|
Schools, Medical
|
|
Concept
|
Medical Order Entry Systems
|
|
Concept
|
Pathology, Molecular
|
|
Concept
|
Renal Insufficiency
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
|
|
Academic Article
|
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Conflict-of-interest policies.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
|
Academic Article
|
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
|
Academic Article
|
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
|
|
Academic Article
|
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
|
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Recommended changes to oncology clinical trial design: revolution or evolution?
|
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
|
Academic Article
|
Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
|
Academic Article
|
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
|
|
Academic Article
|
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
|
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
|
Academic Article
|
User beware: we need more science and less art when measuring financial toxicity in oncology.
|
|
Academic Article
|
The impact of industry on oncology research and practice.
|
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
|
Academic Article
|
Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty.
|
|
Academic Article
|
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.
|
|
Academic Article
|
Oncology Drug Prescribing: The Influences of Greed and Fear.
|
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|